



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12N 15/61, C12Q 1/68 A61K 31/70	A2	(11) International Publication Number: WO 93/23548 (43) International Publication Date: 25 November 1993 (25.11.93)
(21) International Application Number: PCT/US93/04916 (22) International Filing Date: 20 May 1993 (20.05.93) (30) Priority data: 07/886,611 20 May 1992 (20.05.92) US (71) Applicant: VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 40 Allston Street, Cambridge, MA 02139-4211 (US). (72) Inventor: PEATTIE, Debra, A. ; 1716 Cambridge Street, #47, Cambridge, MA 02138 (US). (74) Agents: HALEY, James, F., Jr. et al.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US).		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: METHOD OF DETECTING TISSUE-SPECIFIC FK506 BINDING PROTEIN MESSENGER RNAs AND USES THEREOF (57) Abstract <p>A novel mRNA encoding FK506 binding protein (FKBP12) has been identified in human T lymphocytes. The cDNA corresponding to this mRNA has been sequenced and characterized. The mRNA has been shown to be identical in sequence in two regions to two previously known FKBP-encoding sequences and clearly distinct from the two known sequences in the 3' untranslated region (3'UTR). The tissue-distribution of this mRNA also differs from the tissue distribution of the two known mRNAs. DNA probes derived from this transcript encoding a distinct 3'UTR provide a means to detect FKBP12 mRNA in a tissue-specific manner and to use tissue-specific FKBP12 mRNA to monitor rejection of transplanted tissue, and the effects of FK506 immunosuppressant therapy. Nucleic acid sequences which hybridize to these 3'UTRs may also provide a means to modify <i>in vivo</i> production of tissue-specific FKBP mRNA.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

METHOD OF DETECTING TISSUE-SPECIFIC FK506 BINDING
PROTEIN MESSENGER RNAs AND USES THEREOF

Background of the Invention

5 FK506 and cyclosporin A (CsA) are potent immunosuppressants that block the early steps of T lymphocyte activation. These immunosuppressants interfere with the Ca^{2+} -dependent signaling pathways mediated by the T cell receptor. (Tocci, M.J. et al.,
10 J. Immunol. 143:718-726 (1989); Mattila, P.S. et al., EMBO J. 9:4425-4433 (1990); Bierer, B.E. et al., Proc. Natl. Acad. Sci. USA 87:9231-9235 (1990). This common biological property is strikingly unpredictable from the distinct chemical structures of the two drugs, but
15 can be rationalized by the recent finding that calcineurin, a Ca^{2+} - and calmodulin-dependent serine/threonine phosphatase (Klee, C.B. and Krinks, M.H. Biochemistry 17:120-126 (1978)), is a common target of these immunosuppressants when they are bound
20 to specific intracellular receptors in vitro and in T lymphocytes. (Liu, J. et al., Cell 66:807-815 (1991); Friedman and Weissman, 1991). These receptors, termed immunophilins, apparently play key roles in immunosuppressive mechanisms and potentially offer
25 insight into general cytoplasmic signaling and protein transport mechanisms within cells. (McKeon, F. Cell 66:823-826 (1991).

- 2 -

FKBPs (FK506-binding proteins) are members of a class of immunophilins that form complexes with FK506, as well as with the structurally related immunosuppressive macrolide rapamycin. (Schreiber, S.L. Science 251:283-287 1991). Both FK506 (Harding, M.W. et al., Nature 341:758-760 (1989; Siekierka, J.J. et al., Nature 341:755-757 (1989; Harrison, R.K. and Stein, R.L. Biochemistry 29:3813-3816 (1990) and rapamycin (Bierer B.E. et al., Proc. Natl. Acad. Sci. USA 87:9231-9235 (1990) inhibit the peptidyl-prolyl isomerase activity of FKBPs. The first FKBP to be described at the protein (Harding, M.W. et al., Nature 341:758-760 (1989; Siekerka, J.J. et al., Nature 341:755-757 (1989) and cDNA (Maki, N. et al., Proc. Natl. Acad. Sci. USA 87:5440-5443 (1990; Standaert, R. F. et al., Nature 346:671-674 (1990) levels was FKBP12, an abundant cytosolic immunophilin of M_r 11,800. More recently, FKBP13 (Jin, Y.J. et al., Proc. Natl. Acad. Sci. USA 88:6677-6681 (1991)) and FKBP25 (Galat, A., et al., Biochemistry 31:2427-2434 (1991) have been characterized as immunophilins that bind both FK506 and rapamycin. All of these FKBPs share a core consensus sequence with FKBP12 but only the FKBP12-FK506 complex inhibits calcineurin. This finding implies that the different FKBPs are likely to have diverse effects on signal transduction pathways even though their immunosuppressant binding properties reflect aspects of structural similarity.

The significant immunosuppressive activity of the FKBP12-FK506 complex makes it one of several drugs of choice for prophylactic therapy in transplant patients to prevent tissue rejection (Todo, S., et al., Ann Surg. 212:295-307 (1990); Fung, J. J. et al., Transplant. Proc. 23:2977-2983 (1991)).

- 3 -

Summary of the Invention

The present invention relates to the identification and characterization of a novel messenger RNA (mRNA) encoding an FK506 binding protein in human T lymphocytes and to the sequencing of its corresponding cDNA (SEQ ID NO:1). Sequencing of the cDNA reveals that the mRNA, also referred to as the RNA transcript, is identical in sequence in two regions (i.e., the 5' untranslated region (5'UTR) and the open reading frame region (ORF)) to two known FKBP12-encoding RNA sequences and clearly distinct from the two known sequences in the 3' untranslated region (3'UTR). Furthermore, the tissue distribution of the mRNA of the present invention, which is expressed predominantly in heart, placental and pancreatic tissue, differs from the tissue distribution of the other two mRNAs.

The present invention also relates to isolated DNA which is indicative of tissue-specificity FK506 binding protein mRNAs, and to DNA or RNA probes for use in the detection of nucleic acid sequences (mRNA and DNA) encoding FK506 binding protein mRNA present in specific tissue.

This invention further relates to a method of detecting the expression of tissue-specific FKBP12 mRNA as a means of monitoring tissue rejection in transplant patients. Thus far, indication of tissue rejection has been diagnosed by a combination of clinical, biochemical and pathological criteria. These present methods are complicated, time consuming, and still do not allow early detection. (Todo, S. et al. Ann. Surg. 212:295-307 (1990), Fung, J.J., et al. Transplant. Proc. 23:2977-2983 (1991)). For example, the diagnosis of liver allograft rejection is based on clinical manifestation of fever without a source of infection,

- 4 -

bile output or increased ascites; the biochemical indices of total bilirubin, SGOT, SGPT, alkaline phosphatase and other enzyme levels; and the pathological and histological evidence of tissue inflammation unique to tissue rejection situations.

In a preferred embodiment, RNA from tissue of a human is combined with a DNA or RNA probe which is complementary to all or a portion of the RNA sequence of the 3'UTR of a mRNA encoding FKBP12, the cDNA is shown in SEQ ID NO:2. Detection of hybridization is an indication of the presence of a mRNA encoding FKBP12 in specific tissue. The extent to which FKBP12 is produced can also be determined by western blot analysis of proteins purified from individual tissues. The present method is particularly advantageous because it makes it possible to detect tissue rejection due to an ineffective dosage of FK506 at an earlier stage than is possible with other available methods and, thus, to modify the drug dosage to increase the chances of tissue survival.

The present invention also relates to a method of determining the effects of FK506 therapy on an individual. Clinical management of immunosuppressive therapy treads a fine line between maintaining the optimal drug level which avoids rejection of the transplanted tissue, while minimizing the adverse effects associated with immunosuppressant drugs. Some of these adverse side effects include nephrotoxicity, malignant complications (e.g., posttransplant lymphoproliferative disease), alterations in glucose metabolism and neurotoxicity.

Therefore, it is critical to maintain stringent regulation of FK506 therapy, both in terms of over-all dosage and bioavailability to the specific tissues involved. RNA which is present in specific

- 5 -

tissue of a human can be hybridized to a DNA or RNA probe which is complementary to all or a portion of the RNA sequence of the 3'UTR of an FKBP12 mRNA, the cDNA is shown in SEQ ID NO:2. Detection of hybridization is indicative of mRNA present which encodes FKBP12, and in what amount. The amount of FKBP12 mRNA present is a reasonable indication of the amount of FKBP12 being produced in the target tissue. If insufficient FKBP12 is produced to be effective in immunosuppressive therapy, another line of therapy may be initiated before rejection or toxicity occurs.

The present invention also relates to a method of modifying production of FKBP12 in vivo. In the method, a synthetic oligonucleotide which hybridizes to all or a portion of the 3'UTR of an FKBP12 mRNA can be administered to an individual. The hybridization of the nucleotide sequence could result in modification of the production of FKBP12. In a preferred embodiment, the nucleotide sequence administered will be a DNA sequence, such that when it hybridizes to the 3'UTR of an FKBP12 mRNA translation will be modified.

Brief Description of the Drawings

Figure 1 shows the FKBP12A nucleic acid sequence. (SEQ ID NO: 1).

Figure 2 shows the FKBP12A 3' untranslated region (3'UTR) sequence. (SEQ ID NO: 2).

Figure 3 shows the comparison of the FKBP12A, FKBP12B and FKBP12C, including their respective 3'UTRs. (SEQ ID NOS: 1, 3 and 4 respectively).

Figure 4 shows the electrophoretic gel pattern of human genomic DNA digested with one of five

- 6 -

different restriction endonucleases and then used for Southern analysis.

Figure 5 is a schematic representation of the human FKBP12 gene which spans approximately 17-30 kb and contains five exons that encode three different FKBP12 mRNAs.

Figure 6 is a schematic representation of three FKBP12 mRNAs (12A, 12B, 12C) encoded by the FKBP12 gene (SEQ ID NOS:14-25).

Figure 7A shows results of Northern analysis which indicates that poly(A)+RNA from E⁺T cells enriched from human PBLs contains FKBP12A (0.9 kb), FKBP12B (1.7 kb), and FKBP12C (0.7kb) mRNA transcripts.

Figure 7B shows PCR analysis results of first-strand cDNA transcribed from cytoplasmic RNA and demonstrates that the FKBP12A and FKBP12B mRNAs are produced in an enriched, PHA-stimulated population of T lymphocytes.

Figure 8A shows poly(A)+RNA isolated from enriched populations of human E⁺T cells that were stimulated for 0, 4, 16, or 48 hr with 10 $\mu\text{g ml}^{-1}$ PHA.

Figure 8B shows that a 72 hour exposure of the membrane used in 8A reveals that PHA stimulation also increases the abundance of the 0.9 kb FKBP12A mRNA transcripts.

Figure 9 depicts the electrophoretic gel pattern demonstrating that the 1.7 kb FKBP12 mRNA transcript is present in a variety of human tissues.

Figure 10 is a schematic representation showing the synthetic oligonucleotides and restriction enzyme cleavage sites used to generate probes specific to the different FKBP12 cDNAs and mRNA and the FKBP12 gene (SEQ ID NOS:8-11 and 26-33).

- 7 -

Detailed Description of the Invention

The present invention relates to the identification and characterization of a novel messenger RNA (mRNA) encoding an FK506 binding protein in human T lymphocytes and the sequencing of its corresponding cDNA. Sequencing of the corresponding cDNA revealed that the mRNA, or RNA transcript, is identical in sequence in two regions (i.e., the 5' untranslated region (5'UTR) and the open reading frame region (ORF)) to two known FKBP12-encoding RNA sequences and clearly distinct from the two known sequences in the 3' untranslated region (3'UTR). Furthermore, the tissue distribution of the mRNA of the present invention, which is expressed predominantly in heart, placental and pancreatic tissue, differs from the tissue distribution of the other two mRNAs.

The present invention more particularly relates to the cDNA clone containing an open reading frame that encodes a specific FK506 binding protein hereinafter referred to as FKBP12A (SEQ ID NO: 1), as shown in Figure 1.

As described in detail in Example 1, oligonucleotide probes specific to the FKBP12 open reading frame (ORF) sequence (Maki, N. et al., Proc. Natl. Acad. Sci. USA 87:5440-5443 (1990); Standaert, R.F. et al., Nature 346:671-674 (1990) were used to screen T cell cDNA libraries for other full-length FKBP12 cDNAs. Two different human T lymphocyte cDNA libraries yielded several candidate cDNA clones, and DNA sequence analysis indicated that one of the clones contained the complete FKBP12 ORF. Further analysis showed that the polyadenylated cDNA has a 5'UTR and ORF sequence identical to the cDNAs reported by Maki, N. et al., Proc. Natl. Acad. Sci. USA 87:5440-5443 (1990) and Standaert, R.F. et al., Nature 346:671-674 (1990),

- 8 -

and a 3'UTR distinct from those of the previously known FKBP12 cDNA clones (Figures 2 SEQ ID NO: 12, and 3 SEQ ID NOS: 1, 3 and 4). The newly cloned cDNA was designated FKBP12A (SEQ. ID NO: 1) and the others
5 designated as FKBP12B (SEQ ID NO: 3) (Maki, N. et al., Proc. Natl. Acad. Sci. USA 87:5440-5443 (1990) and FKBP12C (SEQ ID NO: 4) (Standaert, R.F. et al., Nature 346:671-674 (1990)). FKBP12A is 738 base pairs in length and is predicted to encode a protein of 108
10 amino acid residues (SEQ ID NO: 5). This protein sequence is identical to the deduced amino acid sequence of FKBP12 based on two published FKBP12 cDNA sequences. (Standaert, R.F., et al. Nature 346:671-674 (1990); Maki, N. et al., Proc. Natl. Acad. Sci. USA
15 87:5440-5443 (1990)).

As described in detail in Example 2, Southern blot analysis of human genomic DNA was used to determine whether a single FKBP12 gene could encode the FKBP12 mRNAs predicted by the different cDNAs.
20 Radiolabeled DNA fragments specific to the three FKBP12 cDNAs were used as hybridization probes against human genomic DNA cut to completion with one of five restriction endonucleases. Autoradiography revealed a single band in each fractionated digestion when a
25 fragment specific to FKBP12A was used as the probe. (Figure 4, Lane 1 of each digest). Conversely, multiple bands were present when a sequence specific to FKBP12B and FKBP12C was used as the probe (Figure 4, Lane 2). A fragment containing the entire ORF of the
30 cDNAs also produced these multiple bands (Figure 4, Lane 3), with variations only in the Hind III and Pst I digestions. Because the single bands visualized by the FKBP12A-specific probe were contained within each pattern generated by the other probes, it is reasonable
35 to believe that the genomic sequences encoding the

- 9 -

different transcripts are linked. The simplest interpretation of these data suggests that a single FKBP12 gene encodes the different FKBP12 mRNAs and that two or more FKBP12 pseudogenes are specific to the ORF, FKBP12B, and FKBP12C sequences. This interpretation agrees with the report by DiLella, A.G. and Craig, R.J. Biochemistry 30:8512-8517 (1991) that the human FKBP12 gene has four related pseudogenes. As described in Example 3, the FKBP12 gene was then isolated and characterized. Its location was mapped to chromosome 20.

As described in Example 4, Northern hybridization and PCR analysis were used to identify the FKBP12 mRNAs transcribed from the FKBP12 gene. Hybridization analysis revealed that all three FKBP12 mRNAs are transcribed in erythrocyte receptor positive peripheral blood lymphocytes (E⁺PBL's) (Figure 7A). The FKBP12A transcripts were best detected with a 3'UTR probe, presumably because they are less abundant than the FKBP12B and FKBP12C transcripts which compete for an ORF probe. Additionally, FKBP12B transcripts were made visible by autoradiography in half the time required to visualize the FKBP12C transcripts, presumably due to their relative abundance within the cells. These results suggest that the transcript abundance is FKBP12B>FKBP12C>FKBP12A. This interpretation is consistent with the finding that antisense RNA probes were required for efficient detection of the FKBP12A and FKBP12C mRNAs. The FKBP12A 3'UTR probe also hybridized to a 4.7 kb transcript population (Figure 7A, Lane 1) and, to a lesser degree, to two larger transcript populations (approximately 5.7 kb and 7.8 kb, visible in Figure 7A, Lane 2). These could represent cross-hybridizing mRNAs

- 10 -

unrelated to FKBP12 production or precursor populations of mature FKBP12 transcripts.

PCR analysis of first-strand cDNA demonstrated that cytoplasmic RNA of T lymphocytes stimulated with PHA (Figure 7B) contains FKBP12A and FKBP12B transcripts. The amplified FKBP12A sequences were consistently less abundant than the amplified FKBP12B sequences (Lane 2 and 3 in Figure 7B), corroborating the results of Northern analysis. Because FKBP12C is a subset of the FKBP12B sequence, internal primers could not distinguish the two transcript populations in PCR analysis.

Northern analysis also indicated that PHA stimulation of E⁺T lymphocytes increased the cellular abundance of the FKBP12A and FKBP12B transcripts (Figure 8). The RNA isolated from enriched populations of human E⁺T cells (5 µg per lane) was fractionated and probed with a synthetic DNA oligomer specific to 63 nucleotides of the FKBP12 ORF. A 16 hour exposure of the probed membrane reveals that PHA stimulation increases the abundance of the 1.7 kb FKBP12B transcripts. The first two time points examined after stimulation with 10 µg ml⁻¹ PHA, 4 hour and 16 hour, showed a progressive increase in these mRNA levels. The third time point examined, 48 hour, revealed an effect similar to that seen at 16 hour. It is reasonable to use standard laboratory techniques as described above, to determine whether the stimulatory effect could be detected prior to 4 hours and whether the effect was linearly or cyclically progressive. Additionally, hybridization experiments using antisense RNA probes rather than DNA probes would reasonably demonstrate whether FKBP12C transcripts also increase in abundance upon mitogenic stimulation.

- 11 -

Northern analysis demonstrated that the FKBP12 transcripts predominate in poly(A)+RNA from human heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. As shown in Figure 9 each lane contained 2 μ g of poly(A)+RNA from human tissue: H = heart, B = brain, Pl = placenta, Lu = lung, Li = liver, SM = skeletal muscle, K = kidney, Pa = pancreas. The radiolabeled probe was the DNA oligomer described in Figure 8. Positions of RNA molecular weight markers are shown in kb.

Two different probes both indicate the following approximate relative abundance of FKBP12B transcripts: heart=brain=placenta=lung>skeletal muscle=kidney>liver=pancreas. Heart, placental, and pancreatic tissue appear to contain the FKBP12A transcript (faint bands at 0.9 kb in Lanes H, Pl, and P of Figure 9). Heart and placental tissue also contained uncharacterized, faintly hybridizing RNAs around 4.2 kb.

The three FKBP12 transcripts are produced from a single gene that contains five exons (Figures 5 and 6 (SEQ ID NOS:14-25)) and is located on chromosome 20 (DiLella, A.G. and Craig R.J., Biochemistry 30:8512-8517 (1991)). The four intron-exon splice junctions contain the conserved elements characteristic of eukaryotic genes (Figure 5) and FKBP12 is encoded by the first four exons. The fifth exon provides a 3'UTR sequence exclusive to the FKBP12B and 12C transcripts. The four protein-coding exons correspond to the FKBP12 sequence as follows: Exon 1 encodes amino acids 1-11, Exon 2 encodes amino acids 13-27, Exon 3 encodes amino acids 29-65, and Exon 4 encodes amino acids 66-107 (arrows in Figure 3 designate exon junctions). Amino acids 12 and 28 are encoded by codons that are split by exon boundaries. There is a correlation between the

- 12 -

exon-encoded domains of FKBP12 and the structural motifs of the protein (Moore, J.M. et al., Nature 351:248-250 (1991) and DiLella, A.G. and Craig, R.J. Biochemistry 30:8512-8517 (1991)). Structural studies of uncomplexed FKBP12 (Michnick, S.W. et al., Science 252:836-839 (1991); Moore, J.M. et al., Nature 351:248-250 (1991) and the FKBP12/FK506 complex (Van Duyne, G.D. et al. Science 252:839-842 (1991) reveal a common hydrophobic pocket that is defined by residues of the five-stranded antiparallel β -sheet on one face and by residues from a loop and single short helix on the opposite face. The residues that comprise the two central strands of the β -sheet are encoded by Exon 4, and the amino acids that constitute the loop and helical region are encoded by Exon 3. X-ray crystallographic studies of the FKBP-FK506 complex reveal the hydrophobic pocket as the protein site that binds the immunosuppressant (Van Duyne, G.D. et al., Science 252:839-842 (1991), thus demonstrating that the residues encoded by Exons 3 and 4 also correspond to domains of function within FKBP12.

The unique 3'UTRs also suggest that stability, translatability, cellular location, and tissue specificity may affect FKBP12 production. (Jackson, R.J. and Standaert, N., Cell 62: 15-24 (1990); Lipshitz, H.D., Current Opinion in Cell Biology 3:966-975 (1991); Leff, S.E. and Rosenfeld, M.G., Ann. Rev. Biochem. 55:1091-1117 (1986)).

The general phenomenon of pseudogenes is well documented for a variety of eukaryotic genes. (Leff, S.E. et al., Ann. Rev. Biochem. 55:1091-1117 (1986). Poly(A) tails and 3'UTR sequences modulate mRNA half-life and translation efficiency in vivo (Jackson, R.J. and Standart, N. Cell 62:15-24 (1990)). Therefore, transcript diversity generated by these

- 13 -

elements is reasonably viewed as a means to control the final production level of FKBP12 in cells. Additionally, 3'UTRs are known to regulate spatial expression of proteins by controlling proper transcript localization within cells (Lipshitz, H.D. Current Opinion in Cell Biology 3:966-975 (1991). It is reasonable to predict that regulated sequestration and translation of FKBP12 transcripts function to position FKBP12 near specific, localized cellular receptors to effect determined responses.

Finally, alternative 3'UTRs of otherwise identical messages also provide a means to control developmental- or tissue-specific expression of proteins (Leff, S.E. et al., Ann. Rev. Biochem. 55:1091-1117 (1986). It is also reasonable to predict that FKBP12A, FKBP12B and FKBP12C transcripts are regulated in a tissue-specific fashion, because the distribution of FKBP12B transcripts appears greater in heart, brain, placenta, and lung than in skeletal muscle, kidney, liver, and pancreas (Figure 9). This variance could affect the immunophilin:calcineurin ratio postulated to be important for FK506- and CsA-specificity.

Similarly, from the elevated accumulation of mature FKBP12A and FKBP12B transcripts in mitogenically stimulated T lymphocytes (Figure 8), it is reasonable to predict that one result of T cell activation could be increased demand for FKBP12 message, perhaps resulting in elevated FKBP12 levels. Of the three FKBP12 transcripts, the FKBP12A message is the one most likely to be tightly regulated in a tissue-specific fashion, since it does not give rise to the FKBP12 processed pseudogenes (see DiLella, A.G. and Craig, R.J. 1991).

- 14 -

The present invention also relates to isolated DNA, or RNA, having a nucleic acid sequence which is indicative of tissue-specificity of the mRNAs encoding FKBP12. At least three distinct messenger
5 RNAs in human cells can encode FKBP12. Three of these transcripts encoding FKBP12A, FKBP12B and FKBP12C, have been characterized as described above and have been shown to differ only in their 3'UTRs (Figure 3) and their predominant expression in specific mammalian
10 tissue. For example, FKBP12A is expressed in heart, placental and pancreatic tissues; FKBP12B, also found in these tissues, is additionally found in brain, lung, skeletal muscle, kidney and liver, in various quantities. Therefore, it is reasonable to predict
15 that the 3'UTR provides a useful marker sequence to determine tissue-specificity of FKBP12 mRNAs.

The present invention also relates to probes which hybridize to all or a portion of the 3'UTR of FKBP12s, and the use of these probes to detect the
20 presence of tissue-specific FKBP12 mRNAs. For example, one type of DNA probe is comprised of a DNA sequence complementary to the 3'UTR of FKBP12A mRNA. Thus, hybridization of the FKBP12A DNA probe to RNA present in a tissue sample would be useful to detect FKBP12A
25 mRNA present. Alternatively, an RNA probe could be used in a similar manner.

The present invention further relates to a method of monitoring rejection of transplanted tissue, or determining the effects of FK506 therapy to an
30 individual. Production of FKBP12 is essential to form the inhibitory complex of FK506/FKBP12. The FK506/FKBP12 complex acts as a potent immunosuppressant. If insufficient FKBP12 is produced in the target tissue to be effective in
35 immunosuppressive action, modifications of FK506

- 15 -

therapy may be made or another line of therapy may be initiated, before tissue rejection or systemic toxicity occurs.

The present invention also relates to a method of modifying production of FKBP12 in vivo. In the method, a nucleotide fragment, comprising either DNA or RNA complementary to DNA or RNA encoding FKBP12 is administered to an individual and hybridizes to all or a portion of the DNA or RNA encoding an FKBP. It is reasonable to predict that hybridization could result in modified production of the FKBP. For example, the nucleotide sequence administered can be a DNA sequence complementary to the 3'UTR of FKBP12A mRNA. When the sequence hybridizes to the 3'UTR, translation of the mRNA would be inhibited. Thus, production of FKBP12 in specific tissues such as heart, is decreased. A decreased production of heart FKBP12A could result in less competition for FK506 by heart tissue relative to, for example, kidney tissue. If a kidney had been the transplanted organ, the immunosuppressant activity could be concomitantly increased in that specific tissue. Thus, in vivo modification of tissue-specific FKBP12 could increase effective immunosuppressant therapy for targeted tissues.

The present invention further relates to in vivo and in vitro methods of evaluating the effectiveness of an agent as an inhibitor of FKBP12 mRNA production and, thus, usefulness in immunosuppressive therapy. Measurement of an agent as an inhibitor, may be accomplished by first, obtaining a baseline value of FKBP12 mRNA in cells a specific mammalian organ (i.e., the level of FKBP12 mRNA in the cells prior to or in the absence of treatment with an agent to be evaluated for its effectiveness as an immunosuppressant) using nucleic acid probes which

- 16 -

hybridize to all or a portion of the 3'UTR of FKBP12 mRNAs, as described above. The baseline value, is compared with the FKBP12 mRNA level in the same type of cells (e.g., a second sample or cells) after treatment with or in the presence of the agent being evaluated. Lower levels of FKBP12 mRNA after treatment with or in the presence of the agent (i.e., a post-treatment level of FKBP12 mRNA) is an indication that the agent inhibits FKBP12 mRNA production and, thus, can be used in immunosuppressive therapy. In an in vivo embodiment, the agent to be evaluated is administered to a mammal under conditions appropriate for the immunosuppressive agent to act upon production of FKBP12 mRNA. Subsequent to the administration of the agent, presence or absence or relative amounts of FKBP12 mRNA is determined using the nucleic acid probes of the method described. The difference between the baseline value and value obtained subsequent to administration of an agent shown to be an immunosuppressive agent, provides a reasonable basis of evaluating the effectiveness of the immunosuppressive agent in immunosuppressive therapy.

Alternately, cells may be isolated from mammalian tissue of interest, cultured in vitro, and a baseline value indicating the presence of FKBP12 mRNA in the cultured cells obtained as previously described. The cells are then treated with an agent to be evaluated as an immunosuppressant, under conditions appropriate for the agent to act upon production of FKBP12 mRNA in the cultured cells. As described, a lower FKBP12 mRNA level after treatment with or in the presence of an agent is an indication of its ability to inhibit FKBP12 mRNA production. Subsequent to the administration of the immunosuppressive agent, the presence or absence of FKBP12 mRNA is determined, with

- 17 -

the difference between the two values providing a reasonable basis of evaluating the effectiveness of the agent in immunosuppressive therapy.

The present invention will now be illustrated
5 by the following examples, which are not to be seen as limiting in any way.

Example 1: Cloning and DNA Sequencing of FKBP-12A

Candidate FKBP12 cDNA clones were isolated from two human T lymphocyte cDNA libraries. A λ gt10
10 cDNA library (Clontech Laboratories, Inc., Palo Alto, CA) of peripheral blood T cells stimulated with phytohaemagglutinin (PHA) for 48 hr was screened under nonstringent conditions with two synthetic oligomers derived from the open reading frame (ORF) sequence of
15 two FKBP12 cDNAs (Maki, N. et al., Proc.Natl. Acad. Sci. USA 87:5440-5443 (1990); Standaert, R.F. et al., Nature 346:671-674 (1990). The oligomers, (SEQ ID NOS: 6 and 7) were synthesized on an Applied Biosystems 380A DNA synthesizer and were radiolabeled with γ -³²P-
20 ATP. A full-length FKBP12 cDNA obtained from this screen (FKBP12A) was used to screen a second stimulated T lymphocyte cDNA library for additional FKBP12 cDNAs. The genomic clone λ VX18 was obtained by screening an EMBL-3 SP6/T7 library (Clontech) of human placental
25 genomic DNA with ³²P-labeled FKBP12A cDNA under stringent conditions. Genomic clones cVX5 and cVX8 were obtained from a pWE15 cosmid library (Stratagene Cloning Systems, La Jolla, CA) of human placental genomic DNA using hybridization probes under stringent
30 conditions. cVX5 was isolated with a 4.5 kb fragment of λ VX18 that extended from an Sfi I site just outside the SP6 promoter to the closest internal Kpn I site. cVX8 was isolated with a 764 bp fragment specific to the FKBP12B cDNA (generated by PCR using VX10230 and

- 18 -

VX10232 as primers as shown in Figure 10) and was analyzed further after demonstrating that it also hybridized to a 319 bp Ban II/EcoR I fragment specific to the FKBP12 cDNA. The 738 bp cDNA insert of FKBP12A was excised by EcoR I (all restriction enzymes obtained from New England Biolabs, Beverly, MA) digestion and cloned into pUC19 for sequence analysis. Portions of the genomic clones containing sequences homologous to the FKBP12 cDNAs were identified by hybridization and cloned into pUC19 or pGEM®-3Z (Promega, Madison, WI) for sequence analysis. All DNA sequences were determined using α -³⁵S-dATP (Biggin, M.D. *et al.*, Proc. Natl. Acad. Sci. USA 80:3963-3965 (1983) and Sequenase® Version 2.0 DNA sequencing kits (USB, Cleveland, OH). Oligonucleotides were synthesized as required to serve as sequencing primers, and a commercial kit (USB) containing deoxy-7-deazaguanosine triphosphate was used to resolve compressions due to high G and C content (Mizusawa, S. *et al.*, Nucleic Acid Res. 14:1319-1324 (1986)). Both DNA strands were sequenced completely a minimum of two times, and all sequences were analyzed with computer software from DNASTar, Inc. (Madison, WI). The FKBP12A cDNA sequence (SEQ ID NO: 1) has been deposited in GenBank with accession number X52220. The intron and exon sequences of the human FKBP12 gene have been deposited in GenBank with accession numbers M80706, M92422, M92423, and M93060.

Example 2: Southern Analysis of Human Genomic DNA

Human genomic DNA (Clontech Laboratories, Inc. Palo Alto, CA) was digested with the restriction endonucleases BamH I, BsaB I, EcoR I, Hind III, or Pst I and fractionated (10 μ g per lane) in 1% agarose. The DNA was transferred to GeneScreen (New England Nuclear Research Products, Boston, MA) by capillary transfer

- 19 -

using standard conditions and was crosslinked to the membrane with ultraviolet light (Stratalinker, Stratagene Cloning Systems, La Jolla, CA). The DNA probes were radiolabeled using α -³²P-dCTP and a commercial labeling kit (Pharmacia LKB Biotechnology, Piscataway, NJ) and were hybridized at 65°C under stringent conditions. The washed membranes were exposed at -70°C to X-Omat AR x-ray film (Eastman Kodak Company, Rochester, NY) using Cronex Lightning Plus (E.I. DuPont de Nemours and Company, Wilmington, DL) intensifying screens.

As shown in Figure 4, the hybridization probes were as follows: Lane 1 = 319 bp fragment specific to FKBP12A, generated by Ban II/EcoR I digestion of FKBP12A; Lane 2 = 524 bp fragment specific to FKBP12B and FKBP12C generated by PCR amplification of genomic DNA with primers VX10169 (SEQ ID NO:27) and VX10173 (SEQ ID NO:29); Lane 3 = 363 bp fragment, spanning the entire FKBP12 ORF, generated by Dde I digestion of FKBP12A DNA. DNA size markers are shown in kb and were determined by the migration profile of lambda DNA digested with EcoR I and Hind III.

Example 3: Characterization of the FKBP12 Gene and Chromosome Location

Using radiolabeled FKBP12A as a hybridization probe, a lambda library of human placental genomic/DNA was screened at high stringency. Four clones were selected and purified, and DNA from each clone was digested with restriction endonucleases and examined by Southern analysis. All clones hybridized to probes from the ORF, but they exhibited variable hybridization to probes from the 3' termini of the different FKBP12 cDNAs. One clone hybridized specifically to probes derived from the 3'UTRs of FKBP12B and FKBP12C, and sequence analysis indicated this clone was a processed

- 20 -

pseudogene. The three remaining clones hybridized specifically to probes from the 3'UTR of FKBP12A and were extremely similar by restriction enzyme analysis. One of these clones, λ VX18, was analyzed further and proved to be a large portion of the FKBP12 gene.

Mapping studies showed that the λ VX18 insert was approximately 15 kb in size and contained FKBP12A sequences localized at one end (Figure 5). Subcloning and sequence analysis revealed that the clone contained two exons (Exons 3 and 4) separated by a 3.2 kb intron and corresponding to the ultimate 616 bp of the FKBP12A cDNA. Exon 3 contained 113 bp of ORF while Exon 4 contained 126 bp of ORF and the 377 bp FKBP12A 3'UTR (Figure 6). Exon 3 was also contained within the FKBP12B and FKBP12C cDNA sequences, but only the first 165 bases of Exon 4 (the 126 bp of ORF, the TGA stop codon, and the next 36 bp) were found in these cDNA sequences (Figure 6). Additional library screens were performed to isolate genomic clones containing the 5' exons of the FKBP12 mRNAs and the 3' exons of the 12B and 12C mRNAs.

Next, a cosmid library with inserts averaging 38 kb in size was screened. Two independent screening approaches were used: (1) cosmid selection with a fragment from the 5' end of λ VX18 and (2) cosmid selection with a DNA fragment from the 3'UTR of FKBP12B followed by secondary selection with a DNA fragment from the 3'UTR of FKBP12B followed by secondary selection of a clone containing 5' end of the FKBP12 gene; the second approach assumed linkage of the genomic sequences encoding the different FKBP12 cDNAs.

Clone cVX5 was isolated by the first approach and contained the 5' end of the FKBP12 gene; clone cVX8 was isolated by the second approach and contained the entire FKBP12 gene (Figure 5). Subcloning and

- 21 -

sequencing part of cVX5 revealed two exons (Exons 1 and 2) separated by an 80 bp intron. These exons encoded the 5'UTR and first 85 bp of ORF in each FKBP12 cDNA. Specifically, Exon 1 contained the upstream sequence and first 37 bp of ORF while Exon 2 encoded the next 48 bp of ORF (Figure 6). Subcloning and sequencing part of cVX8 identified Exon 5 as the exon encoding the 3' ends of the FKBP12B and 12C mRNAs. DNA sequence from cVX8 also demonstrated directly that the 3'UTR of the FKBP12A transcript lies within the intron between Exons 4 and 5 and is generated by read through of the 3' splice junction of Exon 4 (see Figures 5 and 6). In conjunction with mapping studies of cVX5 and λ VX18, restriction and hybridization analysis of cVX8 indicated that the FKBP12 gene spans between 17-30 Kb.

Using PCR amplification to analyze DNA from human-hamster somatic cell lines representing the entire complement of human chromosomes, it was shown that amplification specific to the FKBP12 gene occurred only with DNA isolated from cell lines that contained human chromosome 20.

Human genomic DNA, genomic DNA from a Chinese hamster ovary cell line, and DNA from human-hamster hybrid somatic cell lines was obtained from Bios Corporation (New Haven, CT), and each was tested by PCR analysis for a sequence specific to the FKBP12 gene. The synthetic oligomers VX10027 and VX10247 (SEQ ID NOS: 8 and 9 respectively) served as the 5' and 3' primers, respectively. Each primer was used at a final concentration of 10 μ M in conjunction with 50 ng of each cell line DNA, and the total reaction volume was 50 μ l. Following 40 rounds of amplification (94°C, 1.5 min; 50°C, 1.5 min; 72°C, 3 min) on a MicroCycler E (Eppendorf, Fremont, CA), 10 μ l of each reaction was fractionated by horizontal gel electrophoresis in 3%

- 22 -

NuSieve agarose (FMC BioProducts) and visualized with ethidium bromide. The amplified DNA fragments were transferred and crosslinked to nylon membrane, and the membrane was probed with two ^{32}P -radiolabeled oligomers
5 VX10171 and VX10174 (SEQ ID NOS: 10 and 11 respectively) internal to the amplified portion of the FKBP12 gene to confirm the identity of the amplified fragment. The amplified product was of the expected size (395 bp) and hybridized to synthetic DNA oligomers
10 derived from the gene sequence and internal to the PCR primers.

Example 4: RNA Preparation, Northern Analysis and PCR Amplification from RNA

Fresh human peripheral blood lymphocytes
15 (PBLs) were obtained from LeukoPaks (Children's Hospital Blood Bank, Boston, MA) derived from random, normal blood donors. The lymphocytes were isolated and separated by density centrifugation over Histopaque-1077 (Sigma Chemical Co., St. Louis, MO) according to
20 the manufacturer's instructions. The population was enriched for T lymphocytes by rosetting with sheep red blood cells for 1 hr at 4°C followed by another centrifugation through Histopaque-1077. Rosetted cells were recovered from the pellet after treatment with
25 0.16 M NH_4Cl , 0.01 M KHCO_3 , 0.1 mM EDTA, pH 7.4. Erythrocyte receptor positive PBLs (E^+ PBLs) were either harvested immediately or were cultured at 37°C at a concentration of 10^7 cells ml^{-1} in RPMI 1640 (Gibco BRL, Grand Island, NY) containing 50 units ml^{-1}
30 penicillin, 50 $\mu\text{g ml}^{-1}$ streptomycin, 2 mM L-glutamine, 50 μM β -mercaptoethanol, 10% heat-inactivated fetal calf serum, 10 mM Hepes pH 7.3 (Gibco BRL), and 10 $\mu\text{g ml}^{-1}$ PHA (Sigma) for 16 hr. All cells were then harvested at 250 x g for 10 min at room temperature and
35 washed twice with Hank's balanced salt solution (Gibco

- 23 -

- BRL). Total RNA was obtained by resuspending the washed cell pellet in 5-10 times its volume in 4.0 M guanidine thiocyanate, 0.1 M Tris-HCl pH 7.5, 1% β -mercaptoethanol and extracting as described by
- 5 Sambrook et al. (1989). Cytoplasmic RNA was purified as described by Gilman (1989). Poly(A)+RNA was selected with an mRNA spin column kit (5 Prime-3 Prime, Boulder, CO), resuspended in ribonuclease-free water, and stored at -70°C until use.
- 10 Poly(A)+RNA for Northern analysis was fractionated in 1% agarose containing formaldehyde before being transferred and crosslinked to nylon membrane as described above. The multiple tissue Northern blot was purchased from Clontech. DNA probes
- 15 were radiolabeled with α -³²P-dCTP as described above while RNA probes were transcribed from fragments cloned into pBluescript® II (Stratagene Cloning Systems La Jolla, CA). The membranes were hybridized, washed, and exposed to x-ray film as described from Southern
- 20 analysis. As shown in Figure 7A, Lane 1 = 20 hr exposure of the membrane; Lane 2 = 44 hr exposure. Marker sizes were determined by the migration profile of lambda DNA digested with EcoR I and Hind III and are indicated in kb.
- 25 RNA was prepared for polymerase chain reaction (PCR) analysis (Mullis, K.B. and Faloona, F.A. Methods Enzymol. 155:335-350 (1987); Saiki, R.K. et al., Science 239:487-491 (1988) using a modification of the procedure described by Brenner, C.A. et al.
- 30 Bio/Techniques 7:1096-1103 (1989). Briefly, cytoplasmic RNA was primed with oligo-dT₁₂₋₁₈ (Collaborative Research, Bedford, MA) and transcribed at 42°C for 1 hr with Moloney murine leukemia virus reverse transcriptase (BRL, Bethesda, MD) before being
- 35 used for PCR reactions. DNA products visible by

- 24 -

ethidium bromide staining after thirty rounds of amplification were obtained using the first-strand cDNA produced from 0.17-1.3 μ g of total cytoplasmic RNA. DNA oligomers used to amplify specific portions of the different FKBP12 mRNAs were as follows: VX10172 (SEQ ID NO:28)-VX10247 (SEQ ID NO:9) for FKBP12A mRNA, VX10027 (SEQ ID NO:8)-VX10173 (SEQ ID NO:29) for FKBP12B mRNA, and VX10172 (SEQ ID NO:28)-VX10028 (SEQ ID NO:26) for the ORF common to all FKBP mRNAs (see Figure 10). A Perkin Elmer Cetus GenAmp 9600 was used for all PCR reactions that involved cytoplasmic RNA, and the DNA products were fractionated on 2% NuSieve 3:1 (FMC BioProducts, Rockland, ME) agarose gels. As shown in Figure 7B, Lane 1 = VX10172 (SEQ ID NO:28)-VX10028 (SEQ ID NO:26): specific to the ORF of all FKBP12 mRNAs, 299 bp fragment expected and obtained; Lane 2 = VX10172 (SEQ ID NO:28)-VX10247 (SEQ ID NO:9): specific to FKBP12A mRNA, 683 bp fragment expected and obtained; Lane 3 = VX10027 (SEQ ID NO:28)-VX10173 (SEQ ID NO:29): specific to FKBP12B mRNA, 607 bp fragment expected and obtained; Lane 4 = VX10201 (SEQ ID NO:30)-VX10801 (SEQ ID NO:33): specific to FKBP12C mRNA, 608 bp fragment expected but not obtained; Lane 5 = control primers SEQ ID NOS: 12 and 13, respectively to produce a 335 bp fragment specific for β 2-microglobulin.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

- 25 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Vertex Pharmaceuticals, Inc.
- (ii) TITLE OF INVENTION: METHOD OF DETECTING TISSUE-SPECIFIC
FK506 BINDING PROTEIN MESSENGER RNAs AND USES THEREOF
- (iii) NUMBER OF SEQUENCES: 33
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: c/o Fish & Neave
 - (B) STREET: 1251 Avenue of the Americas
 - (C) CITY: New York
 - (D) STATE: New York
 - (E) COUNTRY: U.S.A.
 - (F) ZIP: 10020
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 07/886,611
 - (B) FILING DATE: 20-MAY-1992
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Haley Jr., James F.
 - (B) REGISTRATION NUMBER: 27,794
 - (C) REFERENCE/DOCKET NUMBER: VPI92-01 (PCT)
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (212) 596-9000
 - (B) TELEFAX: (212) 596-9090

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 738 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- 26 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CGCGCGCGCG GCTCAGGGTC CGCGCGCGCG ATGGGAGTGC AGGTGGAAAC CATCTCCCA	60
GGAGACGGGC GCACTTCC CAAGCGGGC CAGACTGG TGGTCACTA CACGGGATG	120
CTTGAAGATG GAAAGAAAT TGATTCTOC CGGACAGAA ACAAGCCCT TAAGTTTATG	180
CTAGGCAAGC AGGAGGTGAT CCGAGGCTGG GAAGAAGGG TTGCCAGAT GAGTGTGGT	240
CAGAGAGCA AACTGACTAT ATCTCCAGT TATGCTATG GTGCCACTG GCACCCAGC	300
ATCATCCAC CACATGCCAC TCTGTCTTC GATGTTGAG TTCTAAACT GGAATGACG	360
GAATGGCTC CTCCCTTAC TCCCTGTCT TGGTAAAG AATGGAATAC TGAAGGGCC	420
TTCACGTCT TGTCTCTOC CATGTTATG CCAGGTTTG ATGGTACCA GAGAGACAA	480
AAAACACCAC AAGCTATTT TTCCCTCTG ATCTCTCTG TATGAGTAT CCTTCAGT	540
TTATTAGTGT ATGCTTTGAA TGTAAAAAT GTTACCTTA AGGAAAGAA TTGGCATGT	600
TATGTTCCA GTTCACTCA TGGAGTGGC AGCTTTTAA ATGTTTTCT ATGTAGTTA	660
TAAATTAAAA CTGAATTGAG GACTATGAA ATGTAGGCA AATTGTAGT GCAACATTT	720
TAGTCTTTG GAAAAAA	738

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 374 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CAGGAATGGC CTCTCCCTT AGCTCCCTG TCTGGGTAA GGAATGGAA TACTGAAGG	60
CCCTTCACG CCTTGTCTC TCCATGTA TGCCAGCT TGTGGGTA GCAGAGAA	120
CAAAAACAC CACAAGCTA TTTTCCCC TGCATCTTT CTGTATGAG TATCCTTCA	180
GCTTATTAG TGTATGCTT GAATGAAAA ATGGTCAAC CTAAGGAAAG GAATGGCAT	240
GCTATGTTT CCAGTCAAC TCATGGAGT GCGAGCTGT TAAATTTTT TCTATGAGT	300
TTATAAATTA AAATGAAT GAGGACTAT GAAATGTAG CAAATTTGT AGTCCACA	360
TTTAGTCTT TTGG	374

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1532 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

GAATTGGGGC CGCGGOCAGG TOGCTGTGG TOCAGGCGC CCGTGGGOC GCGCGGCGC      60
TCAGCGTCG CGCGGOCAT GGGAGTGCAG GTGGAACCA TCTCCCCAGG AGACGGGCGC      120
AOCCTCCCCA AGCGGGGCA GACCTGGTGG GTGCACTACA CCGGGATGCT TGAAGATGGA      180
AAGAAATTTC ATTCTCCCG GGACAGAAC AAGCCCTTTA AGTTTATGCT AGGCAAGCAG      240
GAGGATGTC GAGGCTGGGA AGAAGGGGT GCGCAGATGA GTGTGGGTCA GAGAGCCAAA      300
CTGACTATAT CTCCAGATTA TGCTATGGT GCGCTGGGC ACGCAGCAT CATCCACCA      360
CATGCCACTC TGCTCTTGA TGTTGAGCTT CTAAACTGG AATGACAGGA ATGGCTCTCT      420
CCCTAGCTC CCGTCTCTG GATCTGOCAT GGAGGGATCT GGTCCTCCA GACATGTGCA      480
CATGATCCA TATGGAGCTT TTCTGATGT TCACCTCCAC TTGTATAGA CATCTGCGCT      540
GACTGAATGT GTTCTGTAC TCAGCTTGC TTCCGACCC TCCTGTCTCT CTCCCGCTT      600
CTCTCTGAT GTGTGTTAC CTAACTATA TGCCATAAAC CTCAGTTAT TCATTTTATT      660
TTGTTTTCAT TTGGGGGGA AGATTCAGTT TCAGCTTTT GGATATAGGT TTCCAATTAA      720
GTACATGGTC AAGTATTAAC AGCACAAGTG GTAGGTTAAC ATTAGAATAG GAATGGGTG      780
TGGGGGGGGG GTTTCGAAGA ATATTTTATT TTAATTTTTT GGATGAAAT TTATCTATT      840
ATATATTAAA CATCTTCTCT GCTGGCTGC AAAGOCATAG CAGATTGAG GCGCTGTGA      900
GGACTGAATT ACTCTCAAG TTGAGAGATG TCTTTGGGT AAATTAAAG CCTACCTAA      960
AATGAGGTG GGGATGGGA GAGCTTTGC CTCCACCAT CCGCCACC CTCCCTTAA      1020
AOCCTCTGC TTGAAAGTA GATCATGTT ACCTCAATGC TGGCACTAC AGGTATCTGT      1080
CCCTGGGCA GCAGGGAOCT CCGAAGCTT CTTGTGGOC TTTTTTTTTT TTCTCTCTG      1140
GGTTTTCTA ATGGACTTC AGGAATTTG TAATCTATA ACTTCAAG CTCCACCAT      1200
TCTAAATCT TAAGAACTT AATGACAGT TTCAATTGA GGTCCTGTT GTAGACTTA      1260
CACCCAGTA AAGCCAGOC ATCATGACA ATCTTGAAT GTTCTCTTA GAAATGATG      1320
CTGGTCATG CAGCTTCAG ATCTCTGTT TTTGATGCT TGGCTCCCT TCTGATCTC      1380

```

- 28 -

AGTTTCTGG CTTTCTCTOC CTCAGOOOCT TCICAOOCT TIGCTGTCT GIGTAGTGAT 1440
 TIGGIGAGAA ATGTTGCTG CACCTTOOC CCAGCAOCT TTATGAGCT CAAGTTTTAT 1500
 TATTGCAATA AAAGTGCTT ATGCOOCTAT TC 1532

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 583 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CCGCGGOCAT GGGAGTGCAG GIGGAAACCA TCTOOOAGG AGAGGGGGGC AACTTCCCCA 60
 AGCGGGGCOA GACCTGGGIG GIGCACTACA CCGGGATGCT TGAAGATGA AAGAAATTTG 120
 ATTCTOOOG GCACAGAAC AAGOOCTTTA AGTTTATGCT AGGCAAGCAG GAGGTGATOC 180
 GAGGCTGGGA AGAAGGGGTT GOCAGATGA GIGTGGGTCA GAGAGOCAAA CTGACTATAT 240
 CTCAGATTA TGOCATGCT GOCATGGGC AOCAGGOCAT CATOOOCCA CATGOCCTC 300
 TGTCTTGA TGTGAGCTT CTAAACTGG AATGACAGGA ATGGOOCTCT CCGTAGCTC 360
 CCGTCTCTG GATCTGOCAT GGAGGATCT GGTGCTOCA GACATGTGA CATGAGTGA 420
 TATGAGCTT TTCTGATGT TOCACTOCAC TTGTATAGA CATCTGOCCT GACTGAATGT 480
 GTCTCTCAC TCAGCTTGC TTGAGACAC TCCTGTCTCT CTTCOOCTTT CTCTCTGAT 540
 GIGGTTTAC CTAACTATA TGOCATAAAC CTCAGTTAT TCA 583

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 108 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Gly Val Gln Val Glu Thr Ile Ser Pro Gly Asp Gly Arg Thr Phe
 1 5 10 15
 Pro Lys Arg Gly Gln Thr Cys Val Val His Tyr Thr Gly Met Leu Glu
 20 25 30

- 29 -

Asp Gly Lys Lys Phe Asp Ser Ser Arg Asp Arg Asn Lys Pro Phe Lys
 35 40 45
 Phe Met Leu Gly Lys Gln Glu Val Ile Arg Gly Trp Glu Glu Gly Val
 50 55 60
 Ala Gln Met Ser Val Gly Gln Arg Ala Lys Leu Thr Ile Ser Pro Asp
 65 70 75 80
 Tyr Ala Tyr Gly Ala Thr Gly His Pro Gly Ile Ile Pro Pro His Ala
 85 90 95
 Thr Leu Val Phe Asp Val Glu Leu Leu Lys Leu Glu
 100 105

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AACAAGCOCT TTAAGTTTAT G

21

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CATAAACTTA AAGGCCTTGT T

21

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- 30 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CTCGTCCTTG ATGIGGAGC

19

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GTIGGCACCTA CAAATTGGC CTAC

24

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GCCAATTGCT TTGCTTAGGG

20

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GCGCTTCACT GCGTTTGCCT

20

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 23 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- 31 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CTGGGCTAC TCCTCTTTC TGG

23

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GCCTACATGT CTGATCCAC TTAA

24

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GAGACGGUGA GUAG

14

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GCCCCUUCU GUCUCCUAG

20

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- 32 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GGGCA

6

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

ACACGGUGA GUCC

14

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

UACAGUGGUC UUUUCACAG

20

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

GGAUGC

6

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- 33 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GCCCAGGUAU GCUC

14

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CUCCUUGUU CUUUCACAG

20

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

AUGAGU

6

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

UCUUGGGUAA GGAA

14

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- 34 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

AGADUUUUCUG UCCCCAACAG

20

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

AUCUGC

6

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

CATCGAAGAC GAGAGTGGC

19

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

GAGGGATCTG GGGCTOCAG

20

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- 35 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

GAGTGCAGGT GGAAACCATC

20

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

CATCCCCAAC TCAGTTTATG

20

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

GCTCAGGCTC CGGCGCGGCG

20

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GGGGTGAAGA TTCAGTTTCA G

21

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- 36 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

CACTACACAG GACAGCAAAG G

21

(2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 28 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

TTTTTTTTTT TTTTGAATA ACTTGAGG

28

- 37 -

CLAIMS

1. A cDNA clone of mammalian origin encoding an FK506 binding protein which is expressed predominantly in heart tissue, placental tissue and pancreatic tissue.
2. The cDNA clone of claim 1, said clone being of human origin.
3. The cDNA clone of claim 1, said clone comprising all or a portion of the nucleic acid sequence of SEQ ID NO: 1.
4. The cDNA clone of claim 3, said clone consisting essentially of the nucleic acid sequence of SEQ ID NO: 1.
5. An isolated DNA of mammalian origin, said DNA comprising all or a portion of the nucleic acid sequence of SEQ ID NO: 1.
6. The isolated DNA of claim 5, said DNA consisting essentially of the nucleic acid sequence of SEQ ID NO: 1.
7. An isolated DNA which encodes FKBP12 and comprises an untranslated 3'UTR nucleic acid sequence, said sequence being indicative of tissue distribution of FKBP12 mRNA.
8. The isolated DNA of claim 7, said untranslated 3' UTR nucleic acid sequence indicating expression of FKBP12 in RNA by a specific tissue.

- 38 -

9. An isolated DNA, said DNA comprising all or a portion of the nucleotide sequence of SEQ ID NO: 2.

10. The isolated DNA of claim 9, said DNA consisting essentially of the nucleotide sequence of SEQ ID NO: 2.

11. An isolated DNA of mammalian origin which hybridizes to a DNA or RNA fragment having a nucleic acid sequence indicative of tissue specific production of FKBP12 mRNAs.

12. The isolated DNA of claim 11, wherein said DNA hybridizes to a DNA or RNA fragment and comprises an untranslated 3' UTR nucleic acid sequence indicating expression of FKBP12 mRNA by a specific tissue.

13. The isolated DNA of claim 11, said DNA being of human origin.

14. The isolated DNA of claim 11, wherein said DNA hybridizes to all or a portion of the nucleotide sequence of SEQ ID NO: 2.

15. A method of detecting FKBP12 mRNAs expressed in a mammalian tissue, comprising the steps of:

- a) obtaining a sample of mammalian tissue;
- b) preparing the sample of mammalian tissue so as to render RNA present therein available for hybridization with complementary nucleic acid, thereby producing a treated sample;

- 39 -

c) contacting the treated sample with a nucleic acid probe which hybridizes to the 3'UTR of FKBP12 mRNAs; and

d) detecting hybridization of the nucleic acid probe with RNA from the treated sample, wherein hybridization is an indication of the presence of FKBP12 mRNA.

16. The method of claim 15, wherein the nucleic acid probe hybridizes to all or part of the nucleotide sequence of SEQ ID NO: 1.

17. The method of claim 15, wherein the nucleic acid probe hybridizes to all or a part of the nucleotide sequence of SEQ ID NO: 2.

18. A method of monitoring rejection of transplanted mammalian tissue, comprising the steps of:

a) obtaining a sample of transplanted tissue;

b) preparing the sample of transplanted tissue so as to render RNA present in the sample available for hybridization with complementary nucleic acid, thereby producing a treated sample;

c) contacting the treated sample with a nucleic acid probe which hybridizes to the 3'UTR of FKBP12 mRNA; and

d) detecting hybridization of the nucleic acid probe with RNA from the treated sample, wherein hybridization is an indication of the presence of FKBP12 mRNAs.

19. A method of monitoring the effects of FK506 therapy in a mammal comprising the steps of:

- 40 -

- a) obtaining a sample of mammalian tissue;
- b) preparing the sample of mammalian tissue so as to render RNA present therein available for hybridization with complementary nucleic acid, thereby producing a treated sample;
- c) contacting the treated sample with a nucleic acid probe which hybridizes to the 3'UTR of FKBP12 mRNA; and
- d) detecting hybridization of the probe with RNA from the treated sample, wherein the extent of hybridization is indicative of the extent to which FKBP12 mRNA is present in the treated sample and hybridization below a threshold level is indicative of insufficient FKBP12 mRNA level in the tissue.

20. A method of modifying production of FKBP in an individual, comprising administering to the individual a nucleic acid sequence which hybridizes to all or a portion of the 3'UTR of FKBP12 mRNA such that hybridization results in the modified production of FKBP12.

21. The method of claim 15, wherein the nucleic acid sequence is a DNA or RNA sequence which hybridizes to all or a portion of the nucleotide sequence of SEQ ID NO: 1.

22. An in vivo method of evaluating the effectiveness of an agent as an inhibitor of FKBP12 mRNA production in mammalian cells, comprising the steps of:

- a) obtaining a first sample of cells from a mammalian tissue of interest;

- 41 -

b) preparing the first sample of cells so as to render RNA present in the sample available for hybridization with complementary nucleic acid, thereby producing a treated sample;

c) contacting the first sample of treated cells with a nucleic acid probe which hybridizes to the 3'UTR of FKBP12 mRNAs;

d) detecting hybridization of the nucleic acid probe with FKBP12 mRNA from the first sample of treated cells, thereby obtaining a baseline value of FKBP12 mRNA;

e) administering to the mammal the agent to be evaluated, under conditions appropriate for said agent to act upon mRNA production;

f) obtaining a second sample of cells from the mammalian tissue sampled in a);

g) preparing the second sample of treated cells so as to render RNA present therein available for hybridization with complementary nucleic acid, thereby producing a second sample of treated cells;

h) contacting the second sample of treated cells with a nucleic acid probe which hybridizes to the 3' UTR of FKBP12 mRNAs; and

i) detecting hybridization of the nucleic acid probe with FKBP12 mRNA from the second sample of treated cells, thereby obtaining a post-treatment level of FKBP12 mRNA, wherein a lower post-treatment level of FKBP12 mRNA than baseline value is an indication that the agent inhibits FKBP12 mRNA thereby identifying an inhibitor of FKBP12 mRNA production.

23. An in vitro method of evaluating the effectiveness of an agent as an inhibitor of FKBP12

- 42 -

mRNA production in mammalian cells, comprising the steps of:

- a) obtaining cells from mammalian tissue of interest and culturing said mammalian cells under conditions appropriate for growth;
- b) obtaining a first sample of cells from the cultured cells of step a);
- c) preparing said first sample of cells so as to render RNA present in the cells available for hybridization with complementary nucleic acid, thereby producing a first sample of treated cells;
- d) contacting the first sample of treated cells with a nucleic acid probe which hybridizes to the 3'UTR of FKBP12 mRNAs;
- e) detecting hybridization of the nucleic acid probe with FKBP12 mRNA from the first sample of treated cells, thereby obtaining a baseline value of FKBP12 mRNA;
- f) treating said cultured mammalian cells of step a) with the agent to be evaluated, under conditions appropriate for said agent to act upon mRNA production;
- g) obtaining a second sample of cells from the cultured mammalian cells of step f);
- h) preparing the second sample of cells so as to render RNA present therein available for hybridization with complementary nucleic acid, thereby producing a second sample of treated cells;
- i) contacting the second sample of treated cells with a nucleic acid probe which hybridizes to the 3' UTR of FKBP12 mRNAs; and
- j) detecting hybridization of the nucleic acid probe with FKBP12 mRNA from the second sample of treated cells, thereby obtaining a post-

- 43 -

treatment level of FKBP12 mRNA, wherein a lower post-treatment level of FKBP12 mRNA than baseline value is an indication that the agent FKBP12 inhibits mRNA production, thereby identifying an inhibitor of FKBP12 mRNA production.

1/10

FIGURE 1

CCGCCCCGCGCTCAGCGTCCGCGCGCCCATGGGAGTGCAGGTGGAAACCATCTCCCCAG
GAGACGGGCGCACCTTCCCCAAGCGCGGCCAGACCTGCGTGGTGCACTACACCGGGATGCT
TGAAGATGGAAAGAAATTTGATTCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTA
GGCAAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCAGATGAGTGTGGGTCAGA
GAGCCAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTGGGCACCCAGGCATCAT
CCCACCACATGCCACTCTCGTCTTCGATGTGGAGCTTCTAAACTGGAATGACAGGAATGG
CCTCCTCCCTTAGCTCCCTGTTCTTGGGTAAGGAAATGGAATACTGAAGGGCCCTTCACTG
CCTTTGCTCCTCCCATGTTATGCCAGCGTTTGATGGGTAGCAGAGAGAACAAAAACACC
ACAAGGCTATTTTTCCCCCTGCATTCTTTCTGTATTGAGTATCCTTTCAGTGTTATTAGTG
TATGCTTTGAATGTAAAAATTGGTCACCCTAAGGAAAGGAATTGGCATGTGTATGTTCCCA
GTTCAACTCATGGAGATGGCAGCTGTTTAAATGTTTTCTATGTAGTTTATAAATTAAAC
TGAATTGAGGACTATGGAAATGTAGGCCAAATTTGTAGTGCCAACATTTTAGTTCTTTGGA
AAAAAA

SUBSTITUTE SHEET

2/10

FIGURE 2

CAGGAATGGCCTCCTCCCTTAGCTCCCTGTTCTTGGGTAAGGAAATGGAATACTGAAGGGCCCTT
CACTGCCTTTGCTCCTCCCATGTTATGCCCAGCGTTTGATGGGTAGCAGAGAGAACAAAAACAC
CACAAGGCTATTTTTCCCCCTGCATTCTTTCTGTATTGAGTATCCTTTCAGTGTTATTAGTGTAT
GCTTTGAATGTAAAAATTGGTCACCCTAAGGAAAGGAATTGGCATGTGTATGTTCCCAGTTCAAC
TCATGGAGATGGCAGCTGTTTAAATGTTTTCTATGTAGTTTATAAATTAAACTGAATTGAGGA
CTATGGAAATGTAGGCCAAATTTGTAGTGCCAACATTTTAGTTCTTTGG

SUBSTITUTE SHEET

FIGURE 3

12A	-72	GGGCGCGCCG	CGGCGCGCCGCTCAGCGTCCGCGCGCGCGC	
12B				
12C				
12A	1	ATGGGAGTGCAGGTGGAACCATCTCCCGAGGAGACGGCGGCACCTTCCCAAGCGCGGCAGACCTGCGT		
12B	1			
12C	1			
12B	72	GGTGCACTACACCGGATGCTTGAAGATGGAAGAAATTGATTCCTCCGGACAGAAACAGCCCTTTA		
12C	72			
12B	143	AGTTTATGCTAGGCAAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGTTGCCAGATGAGTGTGGGTCAG		
12C	143			
12B	214	AGAGCCAAACTGACTATATCTCCAGATTATGCCATTATGGTGCCACTGGCACCCAGGCATCATCCACACA		
12C	214			
12A	285	TGCCACTCTCGTCTTCGATGTGGAGCTTCTAAAACTGGAATGACAGGAATGGCCTCCTCCCTTAGCTCCCT		
12B	285			
12C	285			
12A	356	GTTCTTGGGTAAGGAAATGGAATACTGAAGGGCCCTTCACTGCCCTTTGCTCCTCCCATGTTATGCCACGG		
12B	356			
12C	356			

4/10

FIGURE 3 (continued)

12A 427 TTTGATGGGTAGCAGAGAGAACAAAAACACCAAGGCTATTTTCCCCCTGCATCTCTTCTGTATTGAG
12B 427 TGATGTTCCACTCCACTTTGTATAGACATCTGCCCTGACTGAATGTGTCTGTCACTCAGCTTTGCTTCCG
12C 427
12A 498 TATCCTTTTCAGTGTTATTAGTGATGCTTTGAATGTAAAAATTGGTCACCCCTAAGGAAAGAAATTGGCATG
12B 498 ACACCTCTGTTTCCCTCTTCCCTTTCTCCTCGTATGTGTGTTTACCTAAACTATATGCCATAAACCTCAAG
12C 498CATAA.....
12A 569 TGTATGTTCCAGTTCAACTCATGGAGATGGCAGCTGTTTAAATGTTTCTATGTAGTTTATAAAATAAA
12B 569 TTATTTCATTTTATTTGTTTTCATTTTGGGCTGAAGATTTCAGTTTCAGTCTTTTGGATATAGGTTTCCAAT
12C 569A_n
12A 640 ACTGAATTGAGGACTATGGAATAATGTAGGCCAAATTTGTAGTGCCCAACATTTTAGTTCTTTGGA_n
12B 640 TAAGTACATGGTCAAGTATTAAACAGCACAAAGTGGTAGGTTAACATTAGAATAGGAATGGTGTGGGGGGG
12B 711 GGGTTTGCAAGAATAATTTTATTTTAAATTTTGGATGAAATTTTATCTATATATATAATTAACATTTCTTGC
12B 782 TGCTGCGCTGCAAGGCCATAGCAGATTGAGGCGCTGTGAGGACTGAATTACTCTCCAAAGTTGAGAGATG
12B 853 TCCTTGGGTTAAATTAAGCCCTACCTAAACTGAGGTGGGATGGGAGAGCCCTTTGCCCTCCACCATTC
12B 924 CCACCCACCCCTCCCTTAAACCCCTCTGCCCTTTGAAAGTAGATCATGTTCACTGCAATGCTGGACACTACAG
12B 995 GTATCTGTCCCTGGGCCAGCAGGACCCTCTGAAGCCCTTCTTTGTGGCCCTTTTCTTTTTCATCTCTGTGGT
12B 1066 TTTTCTAATGGACTTTTCAGGAATTTTGTAATCTCATAAATTTCCAAAGCTCCACCACTTCTTAAATCTTAAG
12B 1137 AACTTTAATTGACAGTTTCAATTGAAGGTGCTGTTGTAGACTTAACACCCAGTGAAAGCCAGCCATCAT
12B 1208 GACAAATCCTTGAATGTTCTCTTAAGAAAAATGATGCTGGTCAATCGCAGCTTCAGCATCTCCTGTTTTTGA
12B 1279 TGCTTGGCTCCCTCTGCTGATCTCAGTTTCCCTGGCTTTTCCCTCCCTCAGCCCTTCTCACCCCTTTTGTGTGT
12B 1350 CCTGTGTAGTGAATTTGGTGAGAAATCGTTGCTGCACCCCTTCCCCCAGCACCATTTATGAGTCTCAAGTTT
12B 1421 ATTATTGCAATAAAAGTGCTTTATGCCCCGGCTTTTCTCA_n

SUBSTITUTE SHEET

5/10




FIG. 4

SUBSTITUTE SHEET

6/10





FIGURE 5

SUBSTITUTE SHEET

7/10

FIGURE 6



☐ = 5' UTR of Exon 1

▨ = ORF sequence

□ = intron sequence

▤ = 36 bp common element

▥ = intron sequence retained as exon sequence in FKBP12A mRNA

▧ = Exon 5 used only in FKBP12B & FKBP12A mRNAs

○ = ATG start

● = TGA stop

AAA = poly(A) tail

	EXON	INTRON	EXON
Splice junction 1/2	GAGACG	GUGAGUAG...GCCCGUCUCUCUCUCUCUCAG (80 bp)	GGCGCA
Splice junction 2/3	ACACCG	GUGAGUCG...UACAGUGGUCUUUUUUCACAG (~10 kb)	GGAUGC
Splice junction 3/4	GCCCAG	GUAUGCUC...CUUCCUUGUCUUUUUUCACAG (3.2 kb)	AUGAGU
Splice junction 4/5	UCUUGG	GUAAGGAA...AGAUUUUCUGUCCCAACAG (~2.2 kb)	ATCTGC

8/10

FIG. 7A





FIG. 7B



SUBSTITUTE SHEET

9/10

H B P I Lu Li S M K P a

0 4 16 48

0 4 16 48

4.7-
3.7-

1.9-
1.7-

0.9-

4.7-
3.7-

1.9-
1.7-

0.9-

4.2-

1.7-


0.9-

FIG. 8A FIG. 8B

FIG. 9

10/10

FIGURE 10



GENE STRUCTURE OF FKBP



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12N 15/61, C12Q 1/68 A61K 31/70	A3	(11) International Publication Number: WO 93/23548 (43) International Publication Date: 25 November 1993 (25.11.93)
(21) International Application Number: PCT/US93/04916 (22) International Filing Date: 20 May 1993 (20.05.93) (30) Priority data: 07/886,611 20 May 1992 (20.05.92) US (71) Applicant: VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 40 Allston Street, Cambridge, MA 02139-4211 (US). (72) Inventor: PEATTIE, Debra, A. ; 1716 Cambridge Street, #47, Cambridge, MA 02138 (US). (74) Agents: HALEY, James, F., Jr. et al.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US).		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 3 February 1994 (03.02.94)
(54) Title: METHOD OF DETECTING TISSUE-SPECIFIC FK506 BINDING PROTEIN MESSENGER RNAs AND USES THEREOF (57) Abstract <p>A novel mRNA encoding FK506 binding protein (FKBP12) has been identified in human T lymphocytes. The cDNA corresponding to this mRNA has been sequenced and characterized. The mRNA has been shown to be identical in sequence in two regions to two previously known FKBP-encoding sequences and clearly distinct from the two known sequences in the 3' untranslated region (3'UTR). The tissue-distribution of this mRNA also differs from the tissue distribution of the two known mRNAs. DNA probes derived from this transcript encoding a distinct 3'UTR provide a means to detect FKBP12 mRNA in a tissue-specific manner and to use tissue-specific FKBP12 mRNA to monitor rejection of transplanted tissue, and the effects of FK506 immunosuppressant therapy. Nucleic acid sequences which hybridize to these 3'UTRs may also provide a means to modify <i>in vivo</i> production of tissue-specific FKBP mRNA.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 93/04916

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 C12N15/61; C12Q1/68; A61K31/70											
II. FIELDS SEARCHED <div style="text-align: right; margin-right: 100px;">Minimum Documentation Searched⁷</div> <table style="width: 100%; border: none;"> <tr> <td style="width: 25%; border: none;">Classification System</td> <td style="border: none;">Classification Symbols</td> </tr> <tr> <td style="border: none;">Int.Cl. 5</td> <td style="border: none;">C12N ; C12Q ; A61K</td> </tr> </table> <div style="text-align: center; margin-top: 10px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched⁸</div>			Classification System	Classification Symbols	Int.Cl. 5	C12N ; C12Q ; A61K					
Classification System	Classification Symbols										
Int.Cl. 5	C12N ; C12Q ; A61K										
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; padding: 5px;">Category¹⁰</th> <th style="width: 70%; padding: 5px;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 20%; padding: 5px;">Relevant to Claim No.¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;"> EMBL Database entry HSFKBP2 , Accession no M92423/M80706; 28 April 1992. PEATTIE, D.A: "The human FKBP12 gene encodes different FKBP12 mRNAs", see nucleotides 3712-4220. <div style="text-align: center;">---</div> </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-23</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;"> BIOCHEMISTRY vol. 30, no. 35, 3 September 1991, EASTON, PA US pages 8512 - 8517 A.G. DILELLA AND R.J.CRAIG 'Exon organization of the human FKBP-12 gene: Correlation with structural and functional protein domains' cited in the application see figure 4 <div style="text-align: center;">---</div> <div style="text-align: right;">-/--</div> </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-23</td> </tr> </tbody> </table>			Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	EMBL Database entry HSFKBP2 , Accession no M92423/M80706; 28 April 1992. PEATTIE, D.A: "The human FKBP12 gene encodes different FKBP12 mRNAs", see nucleotides 3712-4220. <div style="text-align: center;">---</div>	1-23	X	BIOCHEMISTRY vol. 30, no. 35, 3 September 1991, EASTON, PA US pages 8512 - 8517 A.G. DILELLA AND R.J.CRAIG 'Exon organization of the human FKBP-12 gene: Correlation with structural and functional protein domains' cited in the application see figure 4 <div style="text-align: center;">---</div> <div style="text-align: right;">-/--</div>	1-23
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³									
X	EMBL Database entry HSFKBP2 , Accession no M92423/M80706; 28 April 1992. PEATTIE, D.A: "The human FKBP12 gene encodes different FKBP12 mRNAs", see nucleotides 3712-4220. <div style="text-align: center;">---</div>	1-23									
X	BIOCHEMISTRY vol. 30, no. 35, 3 September 1991, EASTON, PA US pages 8512 - 8517 A.G. DILELLA AND R.J.CRAIG 'Exon organization of the human FKBP-12 gene: Correlation with structural and functional protein domains' cited in the application see figure 4 <div style="text-align: center;">---</div> <div style="text-align: right;">-/--</div>	1-23									
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>											
IV. CERTIFICATION <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> <div style="display: flex; align-items: center;"> 2 <div> Date of the Actual Completion of the International Search <div style="text-align: center; margin-top: 10px;">08 OCTOBER 1993</div> </div> </div> </td> <td style="width: 50%; border: none; vertical-align: top;"> <div> Date of Mailing of this International Search Report <div style="text-align: center; margin-top: 10px;">21 -12- 1993</div> </div> </td> </tr> <tr> <td style="border: none; vertical-align: top;"> International Searching Authority <div style="text-align: center; margin-top: 10px;">EUROPEAN PATENT OFFICE</div> </td> <td style="border: none; vertical-align: top;"> Signature of Authorized Officer <div style="text-align: center; margin-top: 10px;">CUPIDO M.</div> </td> </tr> </table>			<div style="display: flex; align-items: center;"> 2 <div> Date of the Actual Completion of the International Search <div style="text-align: center; margin-top: 10px;">08 OCTOBER 1993</div> </div> </div>	<div> Date of Mailing of this International Search Report <div style="text-align: center; margin-top: 10px;">21 -12- 1993</div> </div>	International Searching Authority <div style="text-align: center; margin-top: 10px;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; margin-top: 10px;">CUPIDO M.</div>					
<div style="display: flex; align-items: center;"> 2 <div> Date of the Actual Completion of the International Search <div style="text-align: center; margin-top: 10px;">08 OCTOBER 1993</div> </div> </div>	<div> Date of Mailing of this International Search Report <div style="text-align: center; margin-top: 10px;">21 -12- 1993</div> </div>										
International Searching Authority <div style="text-align: center; margin-top: 10px;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; margin-top: 10px;">CUPIDO M.</div>										

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	<p>NATURE. vol. 346, 16 August 1990, LONDON GB pages 671 - 674 R.F.STANDAERT ET AL. 'Molecular cloning and overexpression of the human FK506-binding protein FKBP' cited in the application see figure 1</p> <p>----</p>	1-23
X	<p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 87, 1 July 1990, WASHINGTON US pages 5440 - 5443 N.MAKI ET AL. 'Complementary DNA encoding the human T-cell FK506-binding protein, a petidylprolyl cis-trans isomerase distinct from cyclophilin' cited in the application</p> <p>---</p>	1-23
X,P	<p>WO,A,9 219 745 (VERTEX PHARMACEUTICALS, INC.) 12 November 1992 see example 4</p> <p>-----</p>	1,2

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 93/04916

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 20 and 22 are directed to a method of treatment of the human body the search has been carried out and based on the alleged effects of the compound.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

